Cause-specific mortality in patients with psoriasis and psoriatic arthritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Cause-specific mortality in patients with psoriasis and psoriatic arthritis. / Skov, L.; Thomsen, S. F.; Kristensen, L. E.; Dodge, R.; Hedegaard, M. S.; Kjellberg, J.

I: British Journal of Dermatology, Bind 180, Nr. 1, 2019, s. 100-107.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Skov, L, Thomsen, SF, Kristensen, LE, Dodge, R, Hedegaard, MS & Kjellberg, J 2019, 'Cause-specific mortality in patients with psoriasis and psoriatic arthritis', British Journal of Dermatology, bind 180, nr. 1, s. 100-107. https://doi.org/10.1111/bjd.16919

APA

Skov, L., Thomsen, S. F., Kristensen, L. E., Dodge, R., Hedegaard, M. S., & Kjellberg, J. (2019). Cause-specific mortality in patients with psoriasis and psoriatic arthritis. British Journal of Dermatology, 180(1), 100-107. https://doi.org/10.1111/bjd.16919

Vancouver

Skov L, Thomsen SF, Kristensen LE, Dodge R, Hedegaard MS, Kjellberg J. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. British Journal of Dermatology. 2019;180(1):100-107. https://doi.org/10.1111/bjd.16919

Author

Skov, L. ; Thomsen, S. F. ; Kristensen, L. E. ; Dodge, R. ; Hedegaard, M. S. ; Kjellberg, J. / Cause-specific mortality in patients with psoriasis and psoriatic arthritis. I: British Journal of Dermatology. 2019 ; Bind 180, Nr. 1. s. 100-107.

Bibtex

@article{1cacc263ce0141cca53ad6d628c63bf6,
title = "Cause-specific mortality in patients with psoriasis and psoriatic arthritis",
abstract = "Background There are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA). Objectives This retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA. Methods Individuals with a hospital‐based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause‐specific mortality in patients with psoriasis or PsA. Results Death rates per 1000 patient‐years (with 95{\%} confidence intervals) vs. controls were 22·3 (19·7–24·9) vs. 13·9 (11·8–16·0) for patients with psoriasis and 10·8 (8·9–12·8) vs. 11·6 (9·6–13·6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1·74, P < 0·001), but not in patients with PsA (HR 1·06, P = 0·19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3·61, 3·02 and 2·71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2·80) and diseases of the respiratory system (HR 1·46). Patients with psoriasis died at a younger age than controls (mean age 71·0 vs. 74·5 years, P < 0·001). Conclusions Patients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.",
author = "L. Skov and Thomsen, {S. F.} and Kristensen, {L. E.} and R. Dodge and Hedegaard, {M. S.} and J. Kjellberg",
year = "2019",
doi = "10.1111/bjd.16919",
language = "English",
volume = "180",
pages = "100--107",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Cause-specific mortality in patients with psoriasis and psoriatic arthritis

AU - Skov, L.

AU - Thomsen, S. F.

AU - Kristensen, L. E.

AU - Dodge, R.

AU - Hedegaard, M. S.

AU - Kjellberg, J.

PY - 2019

Y1 - 2019

N2 - Background There are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA). Objectives This retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA. Methods Individuals with a hospital‐based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause‐specific mortality in patients with psoriasis or PsA. Results Death rates per 1000 patient‐years (with 95% confidence intervals) vs. controls were 22·3 (19·7–24·9) vs. 13·9 (11·8–16·0) for patients with psoriasis and 10·8 (8·9–12·8) vs. 11·6 (9·6–13·6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1·74, P < 0·001), but not in patients with PsA (HR 1·06, P = 0·19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3·61, 3·02 and 2·71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2·80) and diseases of the respiratory system (HR 1·46). Patients with psoriasis died at a younger age than controls (mean age 71·0 vs. 74·5 years, P < 0·001). Conclusions Patients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.

AB - Background There are limited data regarding causes of mortality in patients with psoriasis or psoriatic arthritis (PsA). Objectives This retrospective cohort study evaluated the risk and leading causes of mortality in patients with psoriasis or PsA. Methods Individuals with a hospital‐based diagnosis of PsA or psoriasis were identified using the Danish National Patient Registry. Matched control individuals were identified from the general population. The main outcome measures were risk of death and cause‐specific mortality in patients with psoriasis or PsA. Results Death rates per 1000 patient‐years (with 95% confidence intervals) vs. controls were 22·3 (19·7–24·9) vs. 13·9 (11·8–16·0) for patients with psoriasis and 10·8 (8·9–12·8) vs. 11·6 (9·6–13·6) for patients with PsA. Survival, according to stratified hazard ratios (HRs), was significantly lower in patients with psoriasis than in controls (HR 1·74, P < 0·001), but not in patients with PsA (HR 1·06, P = 0·19). Significantly increased risk of death was observed in patients with psoriasis vs. controls due to a number of causes; the highest risks were observed for diseases of the digestive system; endocrine, nutritional and metabolic diseases; and certain infectious and parasitic diseases (HRs 3·61, 3·02 and 2·71, respectively). In patients with PsA, increased mortality was observed only for certain infectious and parasitic diseases (HR 2·80) and diseases of the respiratory system (HR 1·46). Patients with psoriasis died at a younger age than controls (mean age 71·0 vs. 74·5 years, P < 0·001). Conclusions Patients with severe psoriasis have increased mortality risk compared with matched controls, due to a number of causes. Evidence to support an increased risk for patients with PsA was less convincing.

U2 - 10.1111/bjd.16919

DO - 10.1111/bjd.16919

M3 - Journal article

C2 - 29947129

VL - 180

SP - 100

EP - 107

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -

ID: 230145029